Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancer

Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapyПодробнее

The Future Role of PARP Inhibition in Ovarian CancerПодробнее

Emerging Strategies in Breast Cancer Care Before, During and After SurgeryПодробнее

PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry GeneticsПодробнее

The Latest in Breast Cancer Treatment and Prevention with Anne M. Wallace - Research on AgingПодробнее

PARP Inhibitor Combinations and Future of Ovarian CancerПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

PARP Inhibitors: New Insights & Future of Ovarian Cancer TreatmentПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian CancerПодробнее

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian CancerПодробнее

Dr. Coleman on the Future of PARP Inhibitors in Ovarian CancerПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее

Evaluating Clinical Pathways for Ovarian Cancer Treatment and Maintenance TherapyПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

PARP Inhibitors: Assessing the Clinical Trial LandscapeПодробнее

Updates in PARP inhibition for ovarian cancerПодробнее

Managed Care Implications of the Expanding Role of PARP Inhibitors in OncologyПодробнее

PARP Combinations: The FutureПодробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее

Overcoming resistance to PARP inhibition in ovarian cancerПодробнее